Close
Novotech
Jabsco PureFlo 21 Single Use

News

Amgen To Present At The Morgan Stanley Global Healthcare Conference

Amgen will present at the Morgan Stanley Global Healthcare Conference at 10:30 a.m. ET on Wednesday, Sept. 14, 2016, in New York City. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. ...

Teva to Present at the Wells Fargo 2016 Healthcare Conference

Teva Pharmaceutical Industries Ltd will host a live audio webcast at the Wells Fargo Healthcare Conference. Eyal Desheh will present on Wednesday, September 7, 2016 at 1:10 PM ET. What: Teva Presentation at the Wells Fargo 2016...

Teva to Host Generic Medicines Business Overview on September 9, 2016

Teva Pharmaceutical Industries Ltd. announced that it will host a conference call and live webcast along with a slide presentation on Friday, September 9, 2016 at 8:00 a.m. ET to communicate an overview of the future prospects of Teva...

TG Therapeutics Announces TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder

TG Therapeutics, Inc. announced that the U.S. FDA has granted orphan drug designation for TG-1101 (ublituximab) the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, for the treatment of patients with neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD). ...

Biotie: BTT1023 receives Orphan Drug Designation in the United States

The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation in the United States for Biotie's BTT1023 drug candidate for the treatment of primary sclerosing cholangitis (PSC). PSC is a chronic and progressive fibrotic liver disease...

Mylan Invalidates Two of Teva’s Copaxone® 40 mg/mL Patents Via U.S. Patent and Trademark Office

Mylan N.V. announced that the U.S. Patent and Trademark Office (PTO) has ruled in favor of Mylan in its inter partes review (IPR) proceeding and found all claims of two related Copaxone® 40 mg/mL patents to be unpatentable. The...

Bristol-Myers Squibb and Pfizer to Present New Eliquis Analyses at ESC Congress 2016

Bristol-Myers Squibb Company and Pfizer Inc announced that 19 abstracts (late-breaking, rapid-fire, oral and poster presentations) will be presented at ESC Congress 2016, to be held August 27–31 in Rome, Italy. These new data from post-hoc analyses from ARISTOTLE...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »